To identify the mechanism through which YAP1 and IL6ST are preferentially degraded in HCC cells, we treated Hep3B cells either with lysosomal inhibitors (leupeptin, NH4Cl, or a combination of the two) or with the proteasome inhibitor MG132. The gene discussed is YAP1; the disease is hepatocellular carcinoma.